Johnson & Johnson Announces Additional Data On IMAAVY Throughout 12 Abstracts At European Academy Of Neurology 2026 Congress; Participants Demonstrated Greater Reductions In MG-ADLe Scores; IMAAVY plus SOC Lowered Symptom Severity, Enhanced Daily Functioning At Week 24

뉴스 본문을 불러오고 있어요.

Johnson & Johnson Announces Additional Data On IMAAVY Throughout 12 Abstracts At European Academy Of Neurology 2026 Congress; Participants Demonstrated Greater Reductions In MG-ADLe Scores; IMAAVY plus SOC Lowered Symptom Severity, Enhanced Daily Functioning At Week 24 | 웨이프 WAPE

Johnson & Johnson Announces Additional Data On IMAAVY Throughout 12 Abstracts At European Academy Of Neurology 2026 Congress; Participants Demonstrated Greater Reductions In MG-ADLe Scores; IMAAVY plus SOC Lowered Symptom Severity, Enhanced Daily Functioning At Week 24

기사 요약

관련 종목

댓글 —